LGND — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
$287.54
Market Cap
$5.76B
52W High
$326.63
52W Low
$200.01
ADV30
502,190
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 51,722,000 | 48,449,000 | 17,368,000 | -13,345,000 | 1,532,105,000 | 115,077,000 | 534,783,000 |
| Dec 2025 | 59,666,000 | 56,674,000 | 20,040,000 | 44,784,000 | 1,560,637,000 | 174,927,000 | 543,425,000 |
| Sep 2025 | 115,461,000 | 111,660,000 | 54,098,000 | 117,273,000 | 1,476,772,000 | 139,376,000 | 526,601,000 |
| Jun 2025 | 47,627,000 | 44,720,000 | 9,720,000 | 4,847,000 | 948,604,000 | 67,669,000 | 120,075,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$49,359,000
Investing CF
$-377,322,000
Financing CF
$428,223,000
CapEx
$-11,314,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$5.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$608,088,000
Inventory
$9,126,000
Receivables
$61,047,000
ST Investments
$581,386,000
EBIT TTM
$163,675,000
Pretax Income TTM
$158,960,000
Interest Exp TTM
$4,715,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$274,476,000
EBITDA
$134,447,008
Free Cash Flow
$142,107,376
Enterprise Value
$5,610,537,984
Total Cash
$779,404,992
Total Debt
$451,976,992
Shares Out
20,041,061
Trailing EPS
$7.67
Book Value
$49.79
ROE
17.1%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 268,087,000 | 47,199,000 | 124,453,000 | 1,560,637,000 | 543,425,000 | — | 49,359,000 |
| Dec 2024 | 167,133,000 | 23,021,000 | -4,032,000 | 941,774,000 | 111,335,000 | — | 97,047,000 |
| Dec 2023 | 131,314,000 | 9,821,000 | 52,154,000 | 787,216,000 | 86,303,000 | — | 49,577,000 |
| Dec 2022 | 196,245,000 | 3,037,000 | -33,361,000 | 762,668,000 | 165,183,000 | — | 137,850,000 |
TTM Snapshot
Revenues TTM
$169,360,000
NetIncome TTM
$-34,890,000
OpCashFlow TTM
$0
Assets (Latest)
$941,774,000
Forward EPS
$11.83
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | $5.82B | $96.51 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.84B | $106.92 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.85B | $18.32 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.64B | $68.01 | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.06B | $62.67 | — |
News headlines (Yahoo Finance, 1h cache)
This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026
2026-07-27 18:09 · Yahoo
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-23 11:00 · Yahoo
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls
2026-07-21 13:40 · Yahoo
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More
2026-07-21 11:41 · Yahoo
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings
2026-07-16 23:17 · Yahoo
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
2026-07-14 15:57 · Yahoo
XOMA Royalty Announces Closing of Its Acquisition by Ligand
2026-07-14 13:00 · Yahoo
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
2026-07-14 13:00 · Yahoo
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
2026-07-14 12:15 · Yahoo
Agenus shares surge as company secures up to $340M to advance colon cancer trial
2026-07-13 16:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.